Want to see TSE:MSCL full AI Analyst Report?
MSCL Stock Chart & Stats
C$13.08
-C$0.65(-4.66%)
At close: 4:00 PM EDT
C$13.08
-C$0.65(-4.66%)
Day’s Range― - ―
52-Week RangeC$7.32 - C$18.98
Previous CloseN/A
Volume23.69K
Average Volume (3M)11.40K
Market Cap
C$264.14M
Enterprise ValueC$134.33
Total Cash (Recent Filing)C$61.74M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 25, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding21,216,438
10 Day Avg. Volume12,451
30 Day Avg. Volume11,400
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$35.63Price Target Upside172.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt lowers solvency and refinancing risk while preserving flexibility to fund clinical development. Meaningful equity provides a financial base, although continued losses could reduce this cushion over time.
Regenerative Medicine PlatformA small-molecule regenerative medicine approach could address the underlying muscle-repair problem rather than only symptoms. If clinical efficacy is demonstrated, the platform may support expansion beyond the initial disease focus.
DMD Market OpportunityFocusing on DMD targets a severe condition with substantial unmet medical need, which can support strategic relevance and partnering potential. Successful development could create a meaningful commercial opportunity despite the company’s early stage.
Bears Say
No RevenueThe absence of revenue means the company has not yet demonstrated commercial validation or internal funding capacity. Its outlook remains dependent on successful clinical progress, regulatory advancement and eventual product launch.
Widening LossesLosses have expanded materially while revenue remains absent, indicating rising development spending without operating leverage. Persistent losses can erode equity and increase the need for financing before any product generates revenue.
Persistent Cash BurnSustained negative operating and free cash flow shows that reported losses translate into substantial cash outflows. Continued clinical investment may require additional capital, creating dilution or funding risk if development timelines extend.
Satellos Bioscience News
MSCL FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was C$7.32 and its highest was C$18.98 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is C$264.14M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Nov 25, 2026 which is in 79 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Aug 13, 2026. The company reported -C$0.777 earnings per share for the quarter, missing the consensus estimate of -C$0.725 by -C$0.052.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.82.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 21,216,438 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -C$0.777 in its last earnings report, missing expectations of -C$0.725. Following the earnings report the stock price went down -3.394%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in TSE:MSCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$35.63 (172.38% Upside)
C$35.63 (172.38% Upside)
Blogger Sentiment
Bullish
TSE:MSCL Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth C$287.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
59.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
MSCL Stock 12 Month Forecast
Average Price Target
C$35.63
▲(172.38% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―